Voyager Reports First Quarter 2025 Financial and Operating Results
Provided By GlobeNewswire
Last update: May 6, 2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg –
Read more at globenewswire.com
